They subsequently confirmed that the metastatic ability of pancreatic cancer cells was significantly inhibited by blocking IL-17B/IL-17RB signaling with monoclonal antibodies that targeted IL-17RB [7]. This evidence concerns the gene IL17RB and familial pancreatic carcinoma.